文献速递泌尿生殖与妇科肿瘤放疗

最低PSA是中高危局限前列腺癌根治性放疗联合雄激素剥夺治疗预后的强预测因子

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.
PubMed 文献 · Radiat Oncol · 2017-09-07

单因素分析显示基线PSA、T分期、Gleason评分、放疗剂量、放疗前PSA及最低PSA均与生化复发显著相关,ROC曲线确定最低PSA 0.06 ng/ml为最佳 cutoff 值,多因素分析显示T分期、Gleason评分和最低PSA是生化无病生存的独立影响因素。

要点

  • 最低PSA 0.06 ng/ml是中高危局限前列腺癌根治性放疗联合ADT后生化复发的强独立预测因子。
  • T分期、Gleason评分和最低PSA是多因素分析中影响生化无病生存的独立变量。
  • 基线PSA、年龄和放疗剂量在多因素分析中不是生化无病生存的独立影响因素。

核心结论

  • 最低PSA 0.06 ng/ml是中危或高危局限前列腺癌接受根治性外照射放疗联合雄激素剥夺治疗患者生化无病生存的强独立预测因子。

研究设计与样本

  • 回顾性分析1995年6月至2015年1月间375例NCCN中危或高危局限前列腺癌患者,均接受根治性外照射放疗联合雄激素剥夺治疗。
  • 雄激素阻断中位持续时间10个月(范围3-36个月),放疗中位剂量72 Gy(范围70-78 Gy),中位随访5.8年(范围0.8-16.39年)。
  • 主要研究终点为生化无病生存(BFS)。

主要发现

  • 单因素分析显示基线PSA(p=0.024)、T分期(p=0.001)、Gleason评分(p=0.042)、放疗剂量(p=0.045)、放疗前PSA(p=0.048)和最低PSA(p<0.001)是影响BCR的显著变量。
  • ROC曲线确定最低PSA 0.06 ng/ml为最佳cutoff值,显著预测BCR风险(p<0.001)。
  • 多因素Cox回归分析显示T分期、Gleason评分和最低PSA是影响BFS的独立变量,而基线PSA、年龄和放疗剂量不是。

关键数值与推荐

  • 最低PSA 0.06 ng/ml为预测生化复发的最佳cutoff值(p<0.001)。
  • 多因素分析中T分期、Gleason评分和最低PSA为生化无病生存的独立影响因素。

临床怎么用

  • 对于中危或高危局限前列腺癌接受根治性外照射放疗联合雄激素剥夺治疗的患者,可将最低PSA 0.06 ng/ml作为评估生化复发风险的重要参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to investigate the effect of tumor characteristics and parameters of treatment response in predicting biochemical disease-free survival (BFS) for patients with intermediate or high risk prostate cancer treated by combined definitive external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT). METHODS: Between June 1995 and January 2015, 375 patients with localized prostate cancer and a National Comprehensive Cancer Network (NCCN) intermediate or high risk categories were treated by definitive EBRT and ADT. Median duration of androgen blockade was 10 months (range: 3-36 months); Median radiation dose was 72 Gy (Range: 70-78 Gy). Median follow-up time was 5.8 years (range: 0.8-16.39 years). The main study endpoint was biochemical disease free survival (BFS). RESULTS: Forty seven patients (12.5%) developed biochemical recurrence (BCR) during the observation period. Monovariate analysis identified baseline PSA (bPSA) (p = 0.024), T-stage (p = 0.001), Gleason's score (GS) (p = 0.042), radiation dose (p = 0.045), PSA pre-radiation therapy (p = 0.048), and nadir PSA (nPSA), (p < 0.001) as significant variables affecting BCR. The receiver operating characteristic (ROC) curve identified a nPSA of 0.06 ng/ml as optimal cut-off value significantly predicting the patients' risk of BCR (p < 0.001). Multivariate cox regression analysis revealed T-stage, GS, and nPSA as independent variable affecting BFS, while bPSA, age, and radiation dose were not. CONCLUSION: Nadir PSA at 0.06 is a strong independent predictor of BFS in patients with intermediate or high risk prostate cancer treated by definitive EBRT and ADT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Geara FB, Bulbul M, Khauli RB, et al. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation. Radiat Oncol. 2017. PMID: 28882187. doi:10.1186/s13014-017-0884-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。